$MO — HOLD 📊 | 6 MONTHS THESIS

$MO — HOLD 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $5.4B | EPS $1.32 vs $1.25 🟢 | Margin 54.5% 💡 Consensus expected continued earnings pressure from volume erosion, but the 6% EPS beat ($1.32 vs $1.2462) signals better cost control and mix; however, the market already prices these at a median 15.2x PE, leaving little room for positive re-rating absent a catalyst. 📉 Reward/risk: 1.44:1 🏢 Business Quality: 6/10 - Strong brands and cash flows, but a declining core market, heavy regulation, and litigation overhang keep it from being a high-quality compounder. 📊 Valuation: fair - Current PE 15.2x matches its historical median and is in line with domestic tobacco peers; FCF yield ~8% supports the price, but that is... 📊 Our read: HOLD. Full analysis → https://stockduty.xyz/s/MO0623

🎯 Q1 2026 | Rev $5.4B | EPS $1.32 vs $1.25 🟢 | Margin 54.5%